Compare ENTA & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTA | CGC |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.0M | 401.0M |
| IPO Year | 2012 | 2023 |
| Metric | ENTA | CGC |
|---|---|---|
| Price | $13.30 | $1.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $20.40 | N/A |
| AVG Volume (30 Days) | 156.5K | ★ 2.9M |
| Earning Date | 05-11-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.93 | ★ 84.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,814,000.00 | $12,759,000.00 |
| Revenue This Year | $7.76 | $8.27 |
| Revenue Next Year | N/A | $15.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $7.05 | $0.84 |
| 52 Week High | $17.15 | $2.38 |
| Indicator | ENTA | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 60.45 |
| Support Level | $12.95 | $1.01 |
| Resistance Level | $13.98 | $1.08 |
| Average True Range (ATR) | 0.58 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 61.40 | 84.62 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.